Home › Funds › Frazier Life Sciences Management, L.P. › TRVI
Frazier Life Sciences Management, L.P. position in TRVI
TREVI THERAPEUTICS INC · Health Care
Frazier Life Sciences Management, L.P. reported holding 9,939,447 shares of TRVI (TREVI THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$185.4M, representing 4.04% of its reported portfolio and ranking #6 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed TRVI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Frazier Life Sciences Management, L.P.'s TRVI position evolved
Frazier Life Sciences Management, L.P. first disclosed a stake in TRVI in Q3 2023 at 6,881,090 shares (US$15.0M). The position peaked in Q2 2026 at 9,939,447 shares, worth US$185.4M. Across 12 filings, Frazier Life Sciences Management, L.P. increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 9,939,447 shares valued at US$185.4M. Notable position changes include a 44% increase in Q4 2024 (shares rose 53% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 6.88M | $15.00M | New |
| Q4 2023 | 7.38M | $9.89M | Add |
| Q1 2024 | 7.38M | $25.46M | Hold |
| Q2 2024 | 7.38M | $22.00M | Hold |
| Q3 2024 | 7.38M | $24.65M | Hold |
| Q4 2024 | 10.66M | $43.94M | Add |
| Q1 2025 | 10.26M | $64.53M | Reduce |
| Q2 2025 | 10.26M | $56.12M | Hold |
| Q3 2025 | 10.26M | $93.87M | Hold |
| Q4 2025 | 10.26M | $128.45M | Hold |
| Q1 2026 | 9.94M | $118.58M | Reduce |
| Q2 2026 | 9.94M | $185.37M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRVI and 13F data
TRVI (TREVI THERAPEUTICS INC) is a Health Care company. 64 other funds we track also report a position in TRVI — the largest reported positions include NEA Management Company, LLC (US$246.6M), Vivo Capital, LLC (US$95.0M), Vestal Point Capital, LP (US$57.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRVI
- NEA Management Company, LLC 13.22M sh · $246.59M · Q2 2026
- Vivo Capital, LLC 5.09M sh · $95.02M · Q2 2026
- Vestal Point Capital, LP 3.10M sh · $57.81M · Q2 2026
- MPM BioImpact LLC 3.07M sh · $57.32M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 2.66M sh · $49.61M · Q2 2026
- Artia Global Partners LP 2.21M sh · $41.23M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 2.14M sh · $40.00M · Q2 2026
- First Light Asset Management, LLC 2.10M sh · $39.11M · Q2 2026
- Logos Global Management LP 1.88M sh · $35.06M · Q2 2026
- Affinity Asset Advisors, LLC 1.80M sh · $33.57M · Q2 2026
- Siren, L.L.C. 1.79M sh · $33.33M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.74M sh · $32.50M · Q2 2026
More on Frazier Life Sciences Management, L.P.
FAQ
How long has Frazier Life Sciences Management, L.P. held TRVI?
Frazier Life Sciences Management, L.P. has disclosed TRVI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Frazier Life Sciences Management, L.P.'s current position in TRVI?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 9.94M shares of TRVI (TREVI THERAPEUTICS INC), valued at $185.37M, representing 4.04% of its reported portfolio and ranking #6.
Has Frazier Life Sciences Management, L.P. been buying or selling TRVI?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in TRVI. The position peaked in Q2 2026 at 9.94M shares.
Which other funds hold TRVI?
Other major institutional holders of TRVI include NEA Management Company, LLC, Vivo Capital, LLC, Vestal Point Capital, LP, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.